Scientists aim to predict which pancreatic cancer patients benefit from immunotherapy
NCT ID NCT07271823
First seen Jan 06, 2026 · Last updated Apr 24, 2026 · Updated 16 times
Summary
This study is creating a tool to predict how well immunotherapy works for people with advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood, tumor tissue, and stool samples from 100 patients to analyze proteins, metabolism, and gut bacteria. The goal is to find patterns that show who is most likely to respond to treatment, helping doctors choose the best therapy in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Zhejiang, Hangzhou, 310022, China
Conditions
Explore the condition pages connected to this study.